Lantheus (NASDAQ:LNTH) Shares Gap Up to $67.39

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $67.39, but opened at $75.00. Lantheus shares last traded at $75.54, with a volume of 972,630 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on LNTH shares. JMP Securities restated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. B. Riley lifted their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Finally, StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $104.71.

Lantheus Price Performance

The firm has a market capitalization of $5.15 billion, a P/E ratio of 17.03 and a beta of 0.52. The firm has a 50-day moving average of $62.22 and a 200-day moving average of $62.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. As a group, analysts predict that Lantheus Holdings, Inc. will post 5.96 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last quarter, insiders sold 94,545 shares of company stock valued at $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Several large investors have recently modified their holdings of LNTH. Exchange Traded Concepts LLC bought a new stake in shares of Lantheus in the third quarter worth $68,000. Raymond James Financial Services Advisors Inc. lifted its position in Lantheus by 15.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 7,404 shares of the medical equipment provider’s stock valued at $514,000 after purchasing an additional 970 shares in the last quarter. Shaker Investments LLC OH lifted its position in Lantheus by 268.6% during the third quarter. Shaker Investments LLC OH now owns 27,705 shares of the medical equipment provider’s stock valued at $1,925,000 after purchasing an additional 20,189 shares in the last quarter. Reinhart Partners LLC. lifted its position in Lantheus by 25.9% during the third quarter. Reinhart Partners LLC. now owns 901,520 shares of the medical equipment provider’s stock valued at $62,638,000 after purchasing an additional 185,376 shares in the last quarter. Finally, Citizens National Bank Trust Department lifted its position in Lantheus by 53.8% during the third quarter. Citizens National Bank Trust Department now owns 12,530 shares of the medical equipment provider’s stock valued at $871,000 after purchasing an additional 4,385 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.